Please login to the form below
infections
This page shows the latest infections news and features for those working in and with pharma, biotech and healthcare.
One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
In the PHE study, two doses of the Pfizer/BioNTech vaccine were 93.7% effective at preventing symptomatic infections caused by the Alpha variant, and 88% against the Delta variant.
Latest news
-
EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine
High neutralising antibody titres were also observed in participants with evidence of prior COVID-19 infection, suggesting the vaccine candidate may have the potential to be deployed as a booster vaccine. ... if it can prevent severe COVID-19 and
-
AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront
Suvratoxumab has the potential to transform pulmonary infection management in ventilated patients.
-
Pfizer, BioNTech eye US approval for COVID-19 booster dose
New real-world data, collected over the last month, suggests the jab is 64% effective at preventing infection after both doses, following the emergence of the Delta variant. ... In Israel, COVID-19 cases have been steadily growing since all restrictions
-
Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
Data suggests vaccine is 64% effective at preventing infection caused by Delta variant after two doses. ... New real-world data, collected over the last month, now suggests the jab is 64% effective at preventing infection after both doses, following the
-
Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall
infections. Overall, the vaccine demonstrated 65.2% efficacy against the Delta variant, which was first identified in India.
EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine
AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront
Pfizer, BioNTech eye US approval for COVID-19 booster dose
Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall
More from news
Approximately 8 fully matching, plus 1,093 partially matching documents found.
Latest Intelligence
-
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
Just like we were before COVID-19, we do not have the tools we need to prevent and treat these infections.
-
The pursuit of patient diversity in clinical trials
The trial not only targeted geographies with high infection rates, but it was also designed to ensure the vaccine was developed in countries where the patient population was adequately represented.
-
The need for automation in healthcare
With the NHS left with a huge backlog due to COVID-19 and illnesses such as respiratory tract infections, diarrhoeal diseases, malaria and tuberculosis representing over 90% of deaths in the
-
Follow the user – democratising medical conference design
webinar. With the advent of a highly contagious virus, priorities changed and the wish to avoid infection became as strong as the need to learn about the virus’s implications for
-
AI and accelerated computing ring in new era for healthcare
Researchers worldwide are racing to find effective vaccine and drug candidates to inhibit infection with and replication of SARS-CoV-2, the virus that causes COVID-19.
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
The pursuit of patient diversity in clinical trials
The need for automation in healthcare
Follow the user – democratising medical conference design
AI and accelerated computing ring in new era for healthcare
More from intelligence
Approximately 0 fully matching, plus 82 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
He was previously VP of clinical development and head of oncology and infection at AstraZeneca where he was responsible for building and managing the company's global oncology portfolio.
-
New faces at 90TEN, Lucid Group and Porterhouse
Cook joins 90TEN from Public Health England’s National Infection Service, where she worked as senior communications manager.
-
Recruiters PIR International appoint four new executives
George Owen (above) holds an MSc in Infection and Immunity from UCL and has direct industry experience.
-
Nabriva Therapeutics appoints chief medical officer
Jennifer Schranz will lead the company’s clinical development business. Nabriva Therapeutics, a biopharma focused on treating bacterial infections, has appointed a new chief medical officer in the form of Jennifer
-
Nabriva Therapeutics appoints new chief commercial officer
Bacterial infections focussed Nabriva Therapeutics has appointed Francesco Maria Lavino as its chief commercial officer ahead of the group’s phase III clinical trial for lefamulin - a potential new treatment for ... I am looking forward to working with
New hires at FibroGen, Saniona and Turbine
New faces at 90TEN, Lucid Group and Porterhouse
Recruiters PIR International appoint four new executives
Nabriva Therapeutics appoints chief medical officer
Nabriva Therapeutics appoints new chief commercial officer
More from appointments
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
degree, our main hope for a way out of this pandemic was through the development of a successful vaccine that could limit transmission and reduce the severity of infection. ... More and more bacterial infections that would previously have been treatable
-
#DemandDiversity: We’re calling on the clinical trials industry to include us all
Shocking, isn’t it? It’s been clear for a long time that ethnic minority groups are at higher risk of severe COVID-19 infections.
-
Building the hospital of the future
chance of infection.
-
Remote Patient Monitoring
We all understand the need for social distancing, to manage infection rates and ensure healthcare systems are not overwhelmed.
-
5 ways that lockdowns and restrictions could be affecting our allergies
12. With the risk of COVID-19 infection known to lessen with better ventilation,. ... with the symptoms of a COVID-19 infection.
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
#DemandDiversity: We’re calling on the clinical trials industry to include us all
5 ways that lockdowns and restrictions could be affecting our allergies
More from PMHub
Approximately 2 fully matching, plus 66 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Straight outta lockdown – what’s next for flexible working?
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Onyx Health Launch Creative Studio After Record Year
- Straight outta lockdown – what’s next for flexible working?
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
